Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAILOR trial
2025-523065-16-00Phase 4Authorised
- Sponsor
- Azienda USL di Bologna
- Start
- Jan 2026
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of aspirin, clopidogrel and ticlopidine in ischemic stroke, myocardial infarction (MI) and cardiac morbidity, sponsored by Azienda USL di Bologna. Primary endpoint: 12-month composite cardiovascular outcome. Planned start Jan 2026; status: authorised.
02
Drugs
aspirinclopidogrelticlopidine
03
Conditions
ischemic strokemyocardial infarction (MI)cardiac morbidity
Beyond the preview
Go deeper on 2025-523065-16-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-523065-16-00.